Adaptive Biotechnologies(ADPT)
icon
搜索文档
Adaptive Biotechnologies(ADPT) - 2020 Q1 - Earnings Call Transcript
2020-05-13 11:56
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2020 Results Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Chad Robins - Co-founder and Chief Executive Officer Julie Rubinstein - President Chad Cohen - Chief Financial Officer Harlan Robins – Chief Scientific Officer and Co-Founder Conference Call Participants Brian Weinstein - William Blair Doug Schenkel - Cowen Tycho Peterson - JPMorgan Derik De Bruin - Bank of America David Westenberg - Gu ...
Adaptive Biotechnologies(ADPT) - 2020 Q1 - Quarterly Report
2020-05-13 04:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-090702 ...
Adaptive Biotechnologies(ADPT) - 2019 Q4 - Earnings Call Transcript
2020-02-27 10:15
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Carrie Mendivil – Investor Relations Chad Robins – Co-founder and Chief Executive Officer Julie Rubinstein – President Chad Cohen – Chief Financial Officer Harlan Robins – Chief Scientific Officer and Co-Founder Conference Call Participants Brian Weinstein – William Blair Subbu Nambi – Cowen Ivy Ma - Bank of America Max Smock – BTIG David Westenberg – Guggenheim Securities Op ...
Adaptive Biotechnologies(ADPT) - 2019 Q4 - Annual Report
2020-02-27 05:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (St ...
Adaptive Biotechnologies(ADPT) - 2019 Q3 - Earnings Call Transcript
2019-11-13 11:55
Adaptive Biotechnologies Corp (NASDAQ:ADPT) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Carrie Mendivil - IR Chad Robins - CEO & Co-Founder Julie Rubinstein - President Chad Cohen - CFO Harlan Robins - Chief Scientific Officer & Co-Founder Conference Call Participants Tycho Peterson - JPMorgan Derik De Bruin - Bank of America Merrill Lynch Brian Weinstein - William Blair David Westenberg - Guggenheim Securities Amanda Murphy - BTIG Operator Good afternoon, ladies and g ...
Adaptive Biotechnologies(ADPT) - 2019 Q3 - Quarterly Report
2019-11-13 05:40
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES COR ...
Adaptive Biotechnologies(ADPT) - 2019 Q2 - Earnings Call Transcript
2019-08-14 18:45
Adaptive Biotechnologies Corp (NASDAQ:ADPT) Q2 2019 Earnings Conference Call August 13, 2019 4:30 PM ET Company Participants Carrie Mendivil - IR Chad Robins - CEO & Co-founder Julie Rubinstein - President Harlan Robins - Chief Scientific Officer & Co-Founder Chad Cohen - CFO Conference Call Participants Patrick Donnelly - Goldman Sachs Tycho Peterson - JPMorgan Derik De Bruin - Bank of America Merrill Lynch Doug Schenkel - Cowen Brian Weinstein - William Blair Dave Westenberg - Guggenheim Securities Amanda ...
Adaptive Biotechnologies(ADPT) - 2019 Q2 - Quarterly Report
2019-08-14 04:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 ...